| scholarly article | Q13442814 |
| P50 | author | Julia Wilkerson | Q56488759 |
| Thomas Litman | Q56568931 | ||
| Rob Robey | Q58798575 | ||
| Alan C Heffner | Q79878752 | ||
| Susan E Bates | Q88874526 | ||
| P2093 | author name string | David Levens | |
| Christopher Devor | |||
| Wilfred Stein | |||
| Lois Bangiolo | |||
| Arup R Chakraborty | |||
| Victoria L Luchenko | |||
| P2860 | cites work | Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain | Q27860534 |
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo | Q28510434 | ||
| Chemical phylogenetics of histone deacetylases | Q30977637 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma | Q33394324 | ||
| Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma | Q33726989 | ||
| Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors | Q33926864 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Histone deacetylase inhibitors: emerging mechanisms of resistance. | Q35592607 | ||
| Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration | Q36608727 | ||
| P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 | Q36621938 | ||
| Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy | Q36763539 | ||
| MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor | Q36850845 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment | Q37133945 | ||
| Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. | Q37451892 | ||
| Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. | Q37550149 | ||
| Phase I trial of a new schedule of romidepsin in patients with advanced cancers | Q37667088 | ||
| Developing histone deacetylase inhibitors as anti-cancer therapeutics | Q37856325 | ||
| Finding the place of histone deacetylase inhibitors in prostate cancer therapy. | Q37960198 | ||
| HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications | Q37962333 | ||
| Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models | Q39434331 | ||
| Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters | Q39528900 | ||
| Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage | Q39705077 | ||
| Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance | Q39744464 | ||
| Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks | Q39793584 | ||
| Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression | Q39802117 | ||
| Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. | Q39963673 | ||
| c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression | Q40164688 | ||
| Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation | Q40278633 | ||
| Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study | Q40334140 | ||
| Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action | Q40349894 | ||
| Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. | Q40431883 | ||
| Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines | Q40434292 | ||
| Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. | Q40683613 | ||
| Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. | Q42730361 | ||
| Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells | Q43666601 | ||
| Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report | Q43775906 | ||
| Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines | Q44317132 | ||
| Epigenetic modifiers: basic understanding and clinical development. | Q45976173 | ||
| Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin | Q46121294 | ||
| Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). | Q46988409 | ||
| Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | Q52564601 | ||
| The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. | Q54539131 | ||
| Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells | Q58862259 | ||
| Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells | Q64377137 | ||
| Histone deacetylase inhibitors in cancer therapy | Q73209407 | ||
| P433 | issue | 8 | |
| P921 | main subject | cell death | Q2383867 |
| P304 | page(s) | 1379-1392 | |
| P577 | publication date | 2014-05-28 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin | |
| P478 | volume | 8 |
| Q99711739 | ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest |
| Q64998591 | Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. |
| Q37684405 | Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. |
| Q54967313 | Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma. |
| Q93036448 | Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system |
| Q64077172 | HDAC Regulates Transcription at the Outset of Axolotl Tail Regeneration |
| Q49813665 | HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer |
| Q41924355 | Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. |
| Q40597173 | Kinetics of HIV-1 Latency Reversal Quantified on the Single-Cell Level Using a Novel Flow-Based Technique |
| Q92262103 | Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases |
| Q90632680 | Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma |
| Q30936712 | Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data |
| Q89995921 | Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy |
| Q42064958 | Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors |
| Q90720782 | Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models |
| Q57712790 | Targeting transcription factor lysine acetylation in inflammatory airway diseases |
| Q92702141 | The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells |
| Q50546142 | UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. |
Search more.